PainReform Ltd.

NasdaqCM PRFX

PainReform Ltd. Price to Book Ratio (P/B) on December 30, 2024

PainReform Ltd. Price to Book Ratio (P/B) is NA on December 30, 2024, a NA change year over year. Price to book ratio compares the stock price to the book value per share; above 1 indicates market values company more than its book value.

PainReform Ltd. 52-week high Price to Book Ratio (P/B) is NA on December 30, 2024, which is NA below the current Price to Book Ratio (P/B).
PainReform Ltd. 52-week low Price to Book Ratio (P/B) is NA on December 30, 2024, which is NA below the current Price to Book Ratio (P/B).
PainReform Ltd. average Price to Book Ratio (P/B) for the last 52 weeks is NA.

Key data

Date	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield	Price to Earnings Ratio (P/E)

NasdaqCM: PRFX

PainReform Ltd.

CEO	Dr. Ehud Geller Ph.D.
IPO Date	Sept. 1, 2020
Location	Israel
Headquarters	65 Yigal Alon Street
Employees	7
Sector	Health Care
Industries Pharmaceuticals Clinical Trials

Description

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Key trends

Past 5 years